1月7日，富特科技披露《2025年度向特定对象发行A股股票募集说明书(修订稿)》。本次向特定对象发 行A股股票募集资金总额不超过52,822.22万元，扣除发行费用后拟用于新能源汽车核心零部件智能化生 产制造项目(三期)、新能源汽车车载电源生产项目第二基地购置项目、新一代车载电源产品研发项目、 补充流动资金。 | 序号 | 项目名称 | 投资总额 | 募集资金拟投入金额 | | --- | --- | --- | --- | | | 杜此還沒有些核心不部件智能化生活 制造项目(三期) | 23.424.79 | 23,424.79 | | | 一带回居在井默申露中出印度提瑞 基地购置项目 | 15,960.26 | 15,500.00 | | | 新一代车载电源产品研发项目 | 3.642.43 | 3.642.43 | | 1 | 补充流动资金 | 10.255.00 | 10,255.00 | | | 合计 | 53,282.47 | 52.822.22 | 本次向特定对象发行的股票为境内上市人民币普通股(A股)，每股面值为人民币1.00元。 本次发行采取向特定对象发行股票的方式，公司将在通过深交所审核并 ...

Core Viewpoint - Huafeng Technology (688629.SH) has received approval from the Shanghai Stock Exchange for its application to issue A-shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Issuance Details - The total amount to be raised from the issuance is not to exceed RMB 972.40 million, with net proceeds intended for projects including expansion of high-speed line modules, defense connector base construction, communication connector R&D upgrades, and working capital supplementation [2][3]. - The issuance will involve up to 30 million shares, representing 6.51% of the company's total share capital prior to the issuance, and will not change the company's control [4]. Group 2: Financial Information - The total investment for the high-speed line module expansion project is RMB 449.73 million, with RMB 388 million allocated from the raised funds [3]. - The defense connector base construction project has a total investment of RMB 470.16 million, with RMB 387.40 million planned from the raised funds [3]. - The communication connector R&D upgrade project has a total investment of RMB 80 million, with RMB 60 million planned from the raised funds [3]. - The total investment for all projects amounts to RMB 1.13689 billion, with the total raised funds capped at RMB 972.40 million [3]. Group 3: Shareholder Structure - Changhong Group holds 31.61% of the company's shares and indirectly controls an additional 10.05% through Changhong Innovation Investment and Military Industry Group, totaling 41.66% [4]. - The actual controller of the company is the Mianyang State-owned Assets Supervision and Administration Commission, which holds 90% of Changhong Group [4].

证券研究报告 | 公司点评 gszqdatemark 2026 02 06 年 月 日 如成功实施将改善公司资产负债结构，同时大股东全额认购彰显信心，有 望维护夯实融资渠道。此前，公司于 2023 年成功实施定增，该次定增实 际募集资金 51.24 亿元，华发集团认购 14.6 亿元。本次定增若成功实施， 将改善公司资产负债结构，同时募投项目聚焦核心城市的保交房与高品质 住宅建设，助力巩固其在重点区域的市场竞争力。本次定增由控股股东以 现金方式全额认购，展现大股东对公司长期发展价值的坚定信心及资金实 力。自从万科债券展期事件发生以后，不同房企债券利差有不同程度扩大， 此次大股东的强力支持，有望加强债券投资者的信心，进一步维护和夯实 融资渠道。 公司 2025 年预计亏损，未来随着优质项目结转，业绩有望逐步企稳。公 司发布业绩预告，预计 2025 年营收保持增长，同比上升约 40%。预计 2025 年实现归属于母公司所有者的净利润-90 亿元到-70 亿元。预计 2025 年实现归属于母公司所有者的扣除非经常性损益后的净利润-70 亿元到- 50 亿元。2025 年出现亏损，主要原因是（1）总资产规模减少，符合 ...

证券研究报告 | 公司点评 gszqdatemark 2026 02 06 年 月 日 华发股份（600325.SH） 定增预计募集不超过 30 亿元，大股东全额认购展现强力支持 华发股份发布 2026 年度定增预案，预计募集资金不超过 30 亿元，定增 价格 4.21 元/股。华发股份发布定增预案，拟发行股份数量合计不超过 7.13 亿股，且不超过发行前公司总股本的 30%。预计募集资金总额不超 过 30 亿元人民币。发行对象为公司控股股东珠海华发集团有限公司（华 发集团），其将以现金方式全额认购。本次定增价格为定价基准日前 20 个 交易日公司 A 股股票交易均价，即元/股（4.212 月 3 日公告日当日收盘 价为 4.02 元）。募集资金用途方面，扣除发行费用后将全部用于珠海、绍 兴、成都、杭州等地的 9 个房地产开发项目（文末附用途明细表）。 如成功实施将改善公司资产负债结构，同时大股东全额认购彰显信心，有 望维护夯实融资渠道。此前，公司于 2023 年成功实施定增，该次定增实 际募集资金 51.24 亿元，华发集团认购 14.6 亿元。本次定增若成功实施， 将改善公司资产负债结构，同时募投项目聚焦 ...

Core Viewpoint - The company International Medicine (000516) is facing challenges related to its stock performance and ongoing capital increase plans, amid concerns over major shareholder actions and industry policy changes [1][2][3] Group 1: Stock Performance - As of February 5, 2026, International Medicine's stock closed at 4.95 yuan, down 0.4%, with a turnover rate of 1.41%, trading volume of 311,800 shares, and a transaction value of 155 million yuan [1] - On the same day, there was a net outflow of 14.1651 million yuan from major funds, indicating a short-term reduction in holdings by institutional investors [3] Group 2: Capital Increase and Shareholder Concerns - The company is currently in the process of a non-public offering, but the specific issuance targets have not yet been determined, leading to investor concerns about potential shareholder dilution and stock price impacts [2] - Major shareholder Century Xinyuan has pledged 82.07% of its shares as of mid-January 2026, raising questions about control and financial stability, although the company asserts that the risk is manageable [2] Group 3: Operational Strategies - In response to ongoing healthcare policy reforms, the company is focusing on enhancing operational efficiency and cost control, particularly in specialized medical fields such as neurology, cardiology, and oncology [2][3] - The company is also exploring differentiated business strategies in areas like aesthetic medicine, rehabilitation, and elder care to build competitive advantages and improve service value [2]

Core Viewpoint - The company, New Sharp Co., Ltd. (688257.SH), has announced a plan to issue A-shares to specific investors, aiming to raise up to 1.3157954 billion yuan for various projects and working capital [1][2]. Group 1: Share Issuance Details - The share issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions to be made in cash at the same price [1]. - The pricing benchmark for the shares will be set at no less than 80% of the average trading price over the 20 trading days prior to the issuance date [1]. - The total number of shares to be issued will not exceed 30% of the company's total share capital before the issuance, amounting to a maximum of 75,722,551 shares [1]. Group 2: Fund Utilization - The total amount to be raised is capped at 1.3157954 billion yuan, with the net proceeds intended for investment in several projects, including: - High-performance CNC blade industrial park project: 48.31747 million yuan [2][3] - High-performance rock drilling tool production project: 31.82846 million yuan [2][3] - Precision tool R&D and testing center and headquarters management center: 15.03361 million yuan [2][3] - Supplementing working capital: 364 million yuan [2][3] - The total investment for these projects is approximately 1.3835069 billion yuan, indicating that the company plans to cover the difference through other means [2][3]. Group 3: Company Background and Performance - New Sharp Co., Ltd. was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 27, 2021, with an initial issuance of 23.2 million shares at a price of 62.30 yuan per share [4]. - The company raised a total of 1.445 billion yuan, with a net amount of 1.352 billion yuan after deducting issuance costs, which was 670 million yuan more than initially planned [4]. - As of January 26, the company's stock price reached a historical high of 56.88 yuan, with a reported revenue of 648 million yuan for the third quarter of 2025, reflecting a year-on-year growth of 38.02% [11].

Core Viewpoint - The company, Aolide (688378.SH), has received approval from the Shanghai Stock Exchange for a simplified procedure to issue shares to specific investors, pending final registration approval from the China Securities Regulatory Commission (CSRC) [1] Group 1: Share Issuance Details - The company plans to raise a total of up to 275.71 million yuan (approximately 27.57 million) through this share issuance, which will not exceed 30% of the company's total share capital prior to the issuance [1][2] - The determined issuance price is 22.70 yuan per share, resulting in the issuance of 12,145,907 shares [2] - The funds raised will be allocated to the OLED display core material PSPI production base project and to supplement working capital [1] Group 2: Investor Participation - The issuance will involve specific investors including Citic Fund Management Co., Ltd., Hu Baoxing, Nord Fund Management Co., Ltd., and several private equity funds, all of whom will subscribe to the shares at the same price in cash [2] - All participating investors do not have any related party relationships with the company before and after the issuance [2] Group 3: Shareholding Structure - As of the announcement date, Xuan Jingquan directly holds 21.84% of the company's shares, and Xuan Lingyi holds 9.61%, indicating a significant family control over the company [3] - Post-issuance, Xuan Jingquan, Xuan Lingyi, and Li Jixuan will collectively control 31.84% of the shares, maintaining their status as the controlling shareholders without any change in control [3] - The lead underwriter for this issuance is Dongfang Securities Co., Ltd., with representatives Sun Ping and Lü Xiaobin [3]

证券日报网讯1月26日，雪榕生物（300511）在互动平台回答投资者提问时表示，《上市公司证券发行 注册管理办法(2025年修正)》第九条和第十三条中对交易所主板上市公司有相关规定，公司为深交所创 业板上市公司。关于定增，公司将按照规定和要求及时履行信息披露义务。 ...

Core Viewpoint - In 2025, the resurgence of the "technology bull market" has led to a noticeable recovery in refinancing activities, with public funds actively participating in private placements, achieving significant returns, including projects that have doubled or more in value [1][2]. Group 1: Public Fund Participation - In 2025, public funds invested a total of 11.126 billion yuan in private placement projects, with E Fund leading by contributing 3.125 billion yuan across 12 projects [2]. - Other notable participants included GF Fund with 1.346 billion yuan, and both China Universal Fund and Fortune Fund with 679 million yuan and 530 million yuan respectively, among 21 public funds that each invested over 100 million yuan [2]. Group 2: Market Dynamics - The enthusiasm for public fund participation in private placements is driven by a combination of policy support, industry growth in sectors like semiconductors and AI, and significant market gains from these projects [3]. - The average discount rate for private placements in 2025 was 15.8%, contributing to stable returns despite a slight decrease from 2024 [4]. Group 3: Profitability and Strategies - As of January 23, 2025, several projects had achieved over 100% floating profits, with notable examples like Jinghua New Materials showing a floating profit of 227% [5]. - Fund managers often utilize the discount advantage of private placements to lower their cost basis while simultaneously reducing positions in the secondary market to enhance returns [6]. Group 4: Future Outlook - The supply of private placements is expected to remain robust, with over 260 proposals in 2025, doubling from 2024, and a projected 150-200 projects for 2026 [7]. - Historical data suggests that the annualized return for private placement strategies since 2020 could approach 30%, indicating a favorable outlook for growth-oriented investments [7].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：向特定对象发行股票申请获中国证监会同意注册批复。 公司公告汇总：本次募集资金总额不超过45,000万元，用于正裕智造园（二期）项目及补充流动 资金。 公司公告汇总：控股股东为于乐控股，实际控制人为郑氏三兄弟，合计控制公司59.89%股份。 关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告 浙江正裕工业股份有限公司于近日收到中国证券监督管理委员会出具的《关于同意浙江正裕工业股份有 限公司向特定对象发行股票注册的批复》（证监许可〔2026〕29号），同意公司向特定对象发行股票的 注册申请。批复自同意注册之日起12个月内有效。公司需严格按照报送上海证券交易所的申报文件和发 行方案实施发行，并在发生重大事项时及时报告。公司将根据批复要求及股东会授权，在规定期限内办 理相关事宜并履行信息披露义务。 2025年度向特定对象发行A股股票募集说明书（注册稿） 正裕工业拟向特定对象发行A股股票，募集资金总额不超过45,000万元，用于正裕智造园（二期）项目 及补充流动 ...